Clinical trials: Refractory Ascites
Ascites Hepatic, Ascites, Malignant
QOL and Sarcopenia in Patients With Ascites
Clinical data regarding quality of life in patients with refractory ascites is limited and preceded the development of newer questionnaires that may be more robust.
- Trial name
- NCT05726747
- Testing
- Quality of Life surveys
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Cirrhosis, Ascites
A (M)Ulti-center, Prospective, (O)Pen Label, Uncontrolled Feasibility (S)Tudy to Assess the Safety and Effectiveness of an Automatic Low Flow (A)Scites (Alfa) Pump (I)n Patients With (C)Irrhosis and Refractory or Recurrent Ascites
The study is a multi-center, prospective, open label, uncontrolled feasibility study enrolling 30 patients with refractory or recurrent ascites and cirrhosis at up to 6 sites.
- Trial name
- MOSAIC (NCT02400164)
- Testing
- alfapump system
- Where
- 6 sites in United States, Canada
- Volunteers
- 30 people
- Sponsor
- Sequana Medical N.V.
Cirrhosis
TIPS With Coated Stents for Refractory Ascites in Patients With Cirrhosis
The main end point of the study is to assess survival in cirrhotic patients with refractory ascites treated by TIPS (using PTFE covered stents) vs patients treated by paracentesis + albumin infusion.
- Trial name
- NCT00222014
- Testing
- TIPS, Paracenthese
- Where
- 4 sites in France
- Volunteers
- 55 people
- Sponsor
- University Hospital, Toulouse
Cirrhosis, Refractory/Recurrent Ascites
Role of Midodrine and Tolvaptan in Patients With Cirrhosis With Refractory or Recurrent Ascites
The development of ascites in the natural history of cirrhosis heralds a worsening of the prognosis to 50% survival at 2 years, and this deteriorates to 30-50% at 1 year when the ascites becomes refractory to medical therapy.
- Trial name
- NCT02173288
- Testing
- Standard medical therapy, Tolvaptan, Midodrine
- Where
- India
- Volunteers
- 50 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Ascites, Decompensated Cirrhosis
A Study for Evaluation of BIV201 to Reduce Ascites and Complications in Patients With Cirrhosis and Refractory Ascites
This study evaluates the addition of BIV201 (terlipressin diacetate) as a continuous infusion in addition to standard of care (diuretics and therapeutic paracentesis) for reduction of ascites and complications in adult patients…
- Trial name
- NCT04112199
- Testing
- BIV201 continuous infusion
- Where
- 10 sites in United States
- Volunteers
- 15 people
- Sponsor
- BioVie Inc.
Liver Cirrhosis
Evaluation of Albumin and Midodrine Versus Albumin Alone in Outcome of Refractory Ascites in Patients With Decompensated Cirrhosis.
The project is about evaluation of albumin and midodrine versus albumin alone in outcome of refractory ascites in patients with decompensated cirrhosis. Cirrhosis is a leading cause of disability and mortality worldwide.
- Trial name
- NCT04816240
- Testing
- Midodrine, Albumin, Standard Medical Treatment
- Where
- India
- Volunteers
- 200 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Refractory Ascites
Transjugular Intrahepatic Portosystemic Shunts Improve Survival in Patients With Cirrhosis and Recurrent Ascites
Currently, there is limited evidence regarding the survival benefit of early transjugular intrahepatic portal shunt (TIPS) placement in patients with cirrhosis and recurrent ascites.
- Trial name
- TIPS (NCT06196723)
- Testing
- transjugular intrahepatic portal shunt
- Where
- 3 sites in China
- Volunteers
- 462 people
- Sponsor
- Tang-Du Hospital
Ascites
Impact of Palliative Catheter Placement on the Quality of Life of Patients With Refractory Ascites
The purpose of this study is look at how treatments for ascites affect quality of life. Your quality of life is the ability for you to enjoy the normal things you do.
- Trial name
- NCT01188746
- Testing
- McGill Quality of Life Questionnaire and the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Cirrhosis, Liver, Ascites Hepatic
Refractory Ascites in Patients With Liver Cirrhosis, and the Potential Treatment With 48 Hours Infusion of Ularitide.
This clinical trial intends to investigate the safety, tolerability and efficacy of ularitide on the renal response in patients with liver cirrhosis and refractory ascites for a maximum exposure duration of 48 hours, through a…
- Trial name
- ULA04 (NCT04311489)
- Testing
- Ularitide
- Where
- Denmark
- Volunteers
- 17 people
- Sponsor
- University of Aarhus
Liver Cirrhosis, Refractory Ascites
Infrared Ray Heat Treatment in Liver Cirrhosis Patients With Refractory Ascites
The objective of this study is to evaluate the therapeutic efficacy of Infrared ray heat treatment in hepatic area in cirrhosis patients with refractory ascites.
- Trial name
- NCT01558895
- Testing
- Infrared ray heat treatment, conventional treatment
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- First People's Hospital of Foshan
Liver Cirrhosis
Safety and Efficacy of Small Frequent Paracentesis Using an Indwelling CAtheter Compared With Repeated Large Volume Paracentesis in Cirrhotic Patients With REfractory Ascites
The aim of the study is to assess the efficacy of intermittent small quantity (upto 3L per day) paracentesis through an indwelling catheter for up to 5 days in comparison with large volume paracentesis on decreasing the need for…
- Trial name
- NCT04406298
- Testing
- small quantity paracentesis, Large Volume Paracentesis
- Where
- India
- Volunteers
- 200 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Cirrhosis, Ascites
Spironolactone Versus Spironolactone Plus Furosemide (SVSSF)
The question whether the sequential diuretic therapy, that means using an antialdosteronic drug at first and adding a loop diuretic in nonresponders, is better than the combination of the two diuretics from the beginning…
- Trial name
- SVSSF (NCT00741663)
- Testing
- Spironolactone and furosemide
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- University of Padova
Refractory Ascites in Patients With Cirrhosis
Refractory Ascitis Diagnosis by the Study of Labelled Albumin Pharmacokinetics
Refractory ascites is an indication for liver transplantation, and includes ascites that is resistant to, or intractable by diuretic therapy (International Ascites Club).
- Trial name
- ARAM (NCT02818673)
- Testing
- labelled human serumalbumin (125-I, Séralb®CisBio), labelled albumin (99m-Tc, Vasculocis®, Cisbio)
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Ascites Hepatic
Prospective Evaluation of PleurX Drain for Treatment of Cirrhotic Refractory Ascites
Refractory ascites (fluid build up in the abdomen that can not bet managed by medications) occurs in at least 10% of patients with end stage liver disease (cirrhosis).
- Trial name
- NCT04569565
- Testing
- PleurX catheter
- Volunteers
- 12 people
- Sponsor
- University of Alberta
Refractory or Recurrent Ascites
ALFApump System Versus Standard of Care in Ascites Treatment
This is a multicentre, open, randomised, and controlled trial conducted in sixty (60) patients diagnosed with refractory or recurrent ascites.
- Trial name
- NCT01528410
- Testing
- ALFApump removal of ascites, Large volume paracentesis for removal of ascites
- Where
- 7 sites in Austria, France and 3 more
- Volunteers
- 58 people
- Sponsor
- Sequana Medical N.V.
Liver Cirrhosis, Refractory Ascites
Fiber-Optic Navigation During TIPS Creation: A Prospective Pilot Study
Transjugular intrahepatic portosystemic shunt (TIPS) creation is an established minimally invasive treatment for complications of portal hypertension such as refractory ascites and variceal bleeding.
- Conditions
- Liver Cirrhosis, Refractory Ascites, Variceal Bleeding, Portal Hypertension
- Trial name
- FLIGHT (NCT07470515)
- Testing
- Fiber-Optic Navigation System
- Where
- Austria
- Volunteers
- 30 people
- Sponsor
- Medical University Innsbruck
Refractory Ascites
A Feasibility Study of the Automated Fluid Shunt (AFS) for Automated Ascites Removal
The purpose of this study is to determine whether the Automatic Fluid Shunt (AFS) can reduce the number of paracentesis procedures in patients with refractory ascites.
- Trial name
- NCT00870662
- Testing
- AFS System
- Where
- 2 sites in Czechia
- Volunteers
- 7 people
- Sponsor
- NovaShunt AG
Refractory Malignant Ascites
Oncolytic Virotherapy Plus PD-1 Inhibitor for Patients With Refractory Malignant Ascites
The objective of this study is to evaluate the safety/tolerability efficacy of oncolytic virotherapy combined with Tislelizumab for patients with refractory malignant ascites.
- Trial name
- NCT05303844
- Testing
- H101, Tislelizumab
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Fudan University
Ascites, Liver Cirrhosis
Proximal Splenic Artery Embolization (PSAE) for the Treatment of Refractory Ascites in Decompensated Cirrhosis
The purpose of this study is to learn whether a procedure called Proximal Splenic Artery Embolization (PSAE) can lower the need for repeat fluid drainage in adults with cirrhosis and a buildup of fluid in the abdomen (ascites)…
- Conditions
- Ascites, Liver Cirrhosis, Hypertension, Portal
- Trial name
- NCT07755059
- Testing
- Proximal Splenic Artery Embolization
- Where
- 3 sites in United States
- Volunteers
- 60 people
- Sponsor
- Massachusetts General Hospital
Refractory Malignant Ascites
Analysis of Patients Treated With Bevacizumab Intraperitoneal for the Treatment of Refractory Malignant Ascites
The refractory malignant ascites is a complication of advanced stages of many cancer types. It is characterized clinically by abdominal pressure sensation, shortness of breath and pelvic pain.
- Trial name
- BEVASCITE (NCT02891369)
- Testing
- No intervention. Descriptive study
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Fondation Hôpital Saint-Joseph